Adjuvant Atezolizumab Sustains Survival vs BSC in Stage IB to IIIA NSCLC

被引：0
|
作者：
Vose, Julie M. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Buffett Canc Ctr, Div Hematol Oncol, Omaha, NE 68198 USA
来源：
ONCOLOGY-NEW YORK | 2024年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：44
相关论文
共 50 条
  • [1] IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Zhou, C.
    Das Thakur, M.
    Srivastava, M. K.
    Zou, W.
    Xu, H.
    Ballinger, M.
    Felip, E.
    Wakelee, H.
    Altorki, N. K.
    Reck, M.
    Liersch, R.
    Kryzhanivska, A.
    Harada, M.
    Tanaka, H.
    Hamm, J.
    McCune, S.
    McNally, V.
    Bennett, E.
    Gitlitz, B.
    Novello, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1374 - S1374
  • [2] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
    Chen, Ping
    Yang, Qing
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
    Altorki, N.
    Felip, E.
    Zhou, C.
    Vallieres, E.
    Moiseyenko, V.
    Smolin, A.
    Rittmeyer, A.
    Vereshchako, R.
    Perol, M.
    Schutte, W.
    Fang, J.
    Tao, M.
    Teixeira, E.
    Kim, Y.
    Gitlitz, B.
    Bennett, E.
    Mcnally, V.
    Wu, F.
    Deng, Y.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S845 - S846
  • [4] IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
    Wang, Jie
    Fan, Yun
    Fang, Jian
    He, Jianxing
    Liu, Yunpeng
    Tao, Min
    Altorki, Nasser
    Felip, Enriqueta
    Wakelee, Heather
    Vallieres, Eric
    Belleli, Rossella
    McNally, Virginia
    Bennett, Elizabeth
    Gitlitz, Barbara J.
    Zhou, Caicun
    CANCER RESEARCH, 2024, 84 (07)
  • [5] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
    Kenmotsu, Hirotsugu
    Zhou, Caicun
    Altorki, Nasser
    Felip, Enriqueta
    Vallieres, Eric
    Sugawara, Shunichi
    Sakai, Hiroshi
    Saito, Haruhiro
    Tao, Min
    Kawaguchi, Koji
    Liu, Yunpeng
    Yu, Chong-Jen
    Wu, Qiong
    Lin, Huang
    Wu, Fan
    Bennett, Elizabeth
    Mcnally, Virginia
    Gitlitz, Barbara
    Wakelee, Heather
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
  • [6] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Felip, E.
    Vallieres, E.
    Zhou, C.
    Wakelee, H.
    Bondarenko, I.
    Sakai, H.
    Saito, H.
    Ursol, G.
    Kawaguchi, K.
    Liu, Y.
    Levchenko, E.
    Kislov, N.
    Reck, M.
    Liersch, R.
    McNally, V. A.
    Zhu, Q.
    Ding, B.
    Bennett, E.
    Gitlitz, B.
    Altorki, N. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319
  • [7] Randomized Controlled Study Comparing Adjuvant versus Neo-Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC
    Yang, Xue-Ning
    Zhong, Wen-Zhao
    Ben, Xiao-Song
    Luo, Hong-He
    Wang, Changli
    Wang, Qun
    Qiao, Guibin
    Yan, Hong-Hong
    Wu, Yi Long
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S277 - S278
  • [8] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [9] IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC
    Felip, E.
    Wakelee, H. A.
    Vallieres, E.
    Martinez-Marti, A.
    Goloborodko, O.
    Zhou, C.
    Rittmeyer, A.
    Chella, A.
    Reck, M.
    Csoszi, T.
    Bondarenko, I.
    Kenmotsu, H.
    Schutte, W.
    Ding, B.
    Zhu, Q.
    Ballinger, M.
    Bennett, E.
    Gitlitz, B. J.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S8 - S9
  • [10] Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396.
    Ardeshir-Larijani, Fatemeh
    Mohindra, Nisha Anjali
    Traynor, Anne M.
    Malhotra, Jyoti
    Shum, Elaine
    Ma, Patrick C.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345